Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Japanese Unit Moves Drug For Treating Several Cancers

This article was originally published in PharmAsia News

Executive Summary

Novartis Pharma KK of Japan says it plans to seek approval for a pancreatic-cancer drug as early as next year, after it completes current Phase III trials. The Japanese arm is developing the drug through several stages for various treatments, leading with an application already filed for using it to treat renal cell carcinoma. Novartis Pharma also expects to begin Phase III trials for RAD001 within a year for treating stomach cancer. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts